Glioblastoma—a moving target
The slow development of effective treatment of glioblastoma is contrasted by the rapidly advancing research on the molecular mechanisms underlying the disease. Amplification and overexpression of receptor tyrosine kinases, particularly EGFR and PDGFRA, are complemented by mutations in the PI3K, RB1, and p53 signaling pathways. In addition to finding effective means to target these pathways, we may take advantage of the recent understanding of the hierarchical structure of tumor cell populations, where the progressive expansion of the tumor relies on a minor subpopulation of glioma stem cells, or gliomainitiating cells. Finding ways to reprogram these cells and block their self-renewal is one of the most important topics for future research.
Authors retain copyright of their work, with first publication rights granted to Upsala Mecical Society. Read the full Copyright- and Licensing Statement.